Company / Cash & Equivalents
Steris Cash & Equivalents History
FY2017-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$319.6M
FY2021
5-year range
-
FY2017-FY2021
Trend
+0.0%
vs FY2020
Sector context
#64 of 148
Health Care
What the data says
At $320M, Steris's cash & equivalents ranks #64 of 148 in the Health Care sector. Improved from $283M to $320M over the past 2 years.
Based on SEC 10-K filings.
$320M in FY2021 with a 3-year CAGR of +16.6%.
Improved from $283M to $320M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#64 of 148 in Health CareTop 43% of 148This company $319.6M Sector average $1.2B
▼
-72.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +16.6%, indicating consistent growth.
- In FY2021, cash & equivalents increased 0.0% year-over-year.
- Ranks #64 out of 148 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2018.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | - | - |
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $319.6M | +0.0% |
| FY2020 | $319.6M | +13.0% |
| FY2019 | $282.9M | +40.4% |
| FY2018 | $201.5M | -28.8% |
| FY2017 | $282.9M | +13.7% |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026